AstraZeneca PLC - American Depositary Shares (AZN)
205.55
+1.03 (0.50%)
NYSE · Last Trade: Feb 15th, 9:58 AM EST
Detailed Quote
Previous Close
204.52
Open
205.64
Bid
205.00
Ask
207.89
Day's Range
204.09 - 206.71
52 Week Range
183.63 - 206.71
Volume
2,504,808
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
0.9300 (0.45%)
1 Month Average Volume
3,093,881
Chart
About AstraZeneca PLC - American Depositary Shares (AZN)
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and manufacturing of a wide range of prescription medications. The company's primary areas of expertise include oncology, respiratory diseases, cardiovascular systems, and immunology, with a commitment to advancing innovative treatments that improve patient outcomes. AstraZeneca collaborates with healthcare professionals, researchers, and academic institutions to drive scientific advancements and ensure that their therapies reach those in need. Through its extensive portfolio, the company aims to address some of the world’s most pressing health challenges while maintaining a strong emphasis on sustainability and corporate responsibility. Read More
As the opening bell rang on February 13, 2026, the divergence between the U.S. technology and healthcare sectors reached a historic fever pitch, signaling a fundamental shift in how markets price growth and defense. While the technology sector continues to ride a wave of massive capital investment into artificial
Full results from the positive Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine showed AstraZeneca’s BREZTRI Aerosphere (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) demonstrated statistically significant and clinically meaningful improvements in patients with uncontrolled asthma compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines: Symbicort (budesonide/formoterol fumarate or BFF, a standard therapeutic option), PT009 (BFF in an Aerosphere formulation) and the Symbicort and PT009 treatment groups combined.1 BREZTRI is a single-inhaler, fixed-dose triple-combination of ICS/LABA and a long-acting muscarinic antagonist (LAMA).
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as the pioneer of RNA interference (RNAi) technology, Alnylam has successfully transitioned from a research-heavy enterprise to a fully integrated, profitable commercial leader. With the recent expansion of [...]
As of February 11, 2026, the corporate landscape is undergoing its most significant transformation in half a decade. After two years of high interest rates and regulatory gridlock that chilled the market, 2026 has emerged as the year of the "Strategic Rebound." With the Federal Reserve stabilizing interest rates following
AstraZeneca has proudly awarded $3.4 million to nonprofit organizations in the US through its Accelerate Change Together (ACT) on Health Equity initiative. This effort aims to support programming that prioritizes the social, cultural and linguistic needs of communities that have experienced barriers to care and opportunity.
On February 10, 2026, AstraZeneca (NYSE:AZN) delivered an earnings report that did more than just recap a successful fiscal year; it laid down a definitive challenge to the current titans of the weight-loss drug market. While the pharmaceutical giant reported a robust 9% increase in total revenue to $58.
Date: February 10, 2026 Introduction For years, Gilead Sciences, Inc. (Nasdaq: GILD) was characterized by investors as a "value trap"—a cash-rich biopharma giant that had lost its way after the historic, yet short-lived, success of its Hepatitis C cures. However, as of early 2026, that narrative has shifted dramatically. Gilead has successfully executed a "second [...]
Date: February 10, 2026 Introduction AstraZeneca PLC (NASDAQ: AZN; LSE: AZN) stands today at a critical crossroads of pharmaceutical history. Long recognized as the crown jewel of British biotechnology, the company has transformed itself from a struggling mid-tier player a decade ago into a global oncology and rare-disease juggernaut. As of February 10, 2026, AstraZeneca [...]
In a move that underscores the pharmaceutical industry’s aggressive pivot toward integrated artificial intelligence, AstraZeneca (NASDAQ: AZN) recently announced the full acquisition of Modella AI, a Boston-based pioneer in multimodal foundation models and agentic software. The deal, finalized in January 2026 following a highly successful pilot partnership initiated in mid-2025, marks a watershed moment for [...]
As of February 6, 2026, AstraZeneca PLC (NASDAQ: AZN) stands as a case study in corporate resilience and strategic reinvention. Once a company teetering on the edge of a massive patent cliff a decade ago, the British-Swedish multinational has transformed into a high-growth oncology and rare disease powerhouse. With a market capitalization now rivaling the [...]
The global economic landscape has been jolted in the opening weeks of 2026 as the United States government formalizes a series of aggressive 25% tariff proposals targeting the critical sectors of semiconductors, automobiles, and pharmaceuticals. These measures, framed as essential for national security and domestic industrial revitalization, have sent shockwaves
AstraZeneca and Daiichi Sankyo’s supplemental Biologics License Application (sBLA) for DATROWAY® (datopotamab deruxtecan-dlnk) has been accepted and granted Priority Review in the US for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
The U.S. economy faced a sobering reality check last week as the Bureau of Economic Analysis (BEA) released a trade report on January 29, 2026, revealing a deficit that widened far beyond initial expectations. While economists had penciled in a consensus forecast of -$43.4 billion, the final
